Grant: SPOR Networks in Chronic Disease - LOI
University of Calgary
$49,754.00
PARTNERS - Patient Assisted Research Transforming National Effectiveness in Rare Diseases. Creating Pathways Toward Improved Care Delivery, Outcomes and Reduced Burden.
FY 2014-15
Summary
A rare disease is a condition that affects less than 1 in 2,000 people. Worldwide it has been estimated that about 6 - 8% of the population is affected by a rare disease. This means between 2. 1 and 2.8 million Canadians are affected. To date, over 6,000 different rare diseases have been identified. Eighty percent of these have a genetic cause and half occur in childhood. Thirty percent of people with a rare disease die before 5 years of age. Rare diseases have significant economic and societal costs including wasted healthcare dollars due to delays in diagnosis and treatments. Families facing a rare disease diagnosis have difficulty accessing the medical care and treatments that most Canadians take for granted. This SPOR Network will work together with Canadian rare disease patients and their families to implement a clinical care and research strategy to improve outcomes and reduce burden by 2021.
PARTNERS (Patient Assisted Research Transforming National Effectiveness in Rare Diseases) will establish unprecedented clinical research capacity directly aimed at improving patient experiences by establishing pan-Canadian clinical care pathways for rare disease patients. Patients with rare diseases have significant challenges with shared cross-cutting themes unrelated to a specific disease. PARTNERS will focus on clinical care activities including but not limited to: cardiac care, cognitive care and treatments, early diagnostics based on genomics, knowledge translation, nutrition and nutritional intervention, rehabilitation and respiratory care. This will allow the Network to maximize patient benefit across the full rare disease spectrum and particularly to impact patients lacking a clear diagnosis. The Network will also focus on clinical trial readiness with improved training for investigators, novel and innovative design, implementation and data analysis, and a rare disease registry to enhance recruitment effectiveness and minimize trial costs.
Department
Program
SPOR Networks in Chronic Disease - LOI
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
323906
Name
Korngut Lawrence W
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
SPOR Networks in Chronic Disease
Projecttitle
PARTNERS - Patient Assisted Research Transforming National Effectiveness in Rare Diseases. Creating Pathways Toward Improved Care Delivery, Outcomes and Reduced Burden.
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$49,754
Cihrequipment2
$0
Programname2
SPOR Networks in Chronic Disease - LOI
Keyworddelim
Cardiac Care; Cognitive Complications; Genomics; Interdisciplinary Care; Knowledge Translation; Nutritional Interventions; Rare Disease; Rehabilitation; Respiratory Care; Translational Research
Abstract
A rare disease is a condition that affects less than 1 in 2,000 people. Worldwide it has been estimated that about 6 - 8% of the population is affected by a rare disease. This means between 2. 1 and 2.8 million Canadians are affected. To date, over 6,000 different rare diseases have been identified. Eighty percent of these have a genetic cause and half occur in childhood. Thirty percent of people with a rare disease die before 5 years of age. Rare diseases have significant economic and societal costs including wasted healthcare dollars due to delays in diagnosis and treatments. Families facing a rare disease diagnosis have difficulty accessing the medical care and treatments that most Canadians take for granted. This SPOR Network will work together with Canadian rare disease patients and their families to implement a clinical care and research strategy to improve outcomes and reduce burden by 2021.
PARTNERS (Patient Assisted Research Transforming National Effectiveness in Rare Diseases) will establish unprecedented clinical research capacity directly aimed at improving patient experiences by establishing pan-Canadian clinical care pathways for rare disease patients. Patients with rare diseases have significant challenges with shared cross-cutting themes unrelated to a specific disease. PARTNERS will focus on clinical care activities including but not limited to: cardiac care, cognitive care and treatments, early diagnostics based on genomics, knowledge translation, nutrition and nutritional intervention, rehabilitation and respiratory care. This will allow the Network to maximize patient benefit across the full rare disease spectrum and particularly to impact patients lacking a clear diagnosis. The Network will also focus on clinical trial readiness with improved training for investigators, novel and innovative design, implementation and data analysis, and a rare disease registry to enhance recruitment effectiveness and minimize trial costs.
Competitiondate
201501
Approvedterm2
1 yr 0 mth
Pinamesdelim
Korngut, Lawrence W; Campbell, Jeffery; Boycott, Kym M; Zinman, Lorne
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $49,754~ $0~